SID 26681509 (quarterhydrate)

SID 26681509 quarterhydrate is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 quarterhydrate inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 quarterhydrate shows no inhibitory activity against cathepsin G[1].

Product Specifications

UNSPSC

12352005

Target

Cathepsin; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/sid-26681509-quarterhydrate.html

Purity

98.02

Solubility

DMSO : 50 mg/mL (ultrasonic) |Ethanol : 5 mg/mL (ultrasonic; warming)

Smiles

O=C(NNC(SCC(NC1=CC=CC=C1CC)=O)=O)[C@H](CC2=CNC3=CC=CC=C23)NC(OC(C)(C)C)=O.[1/4].O

Molecular Formula

C27H33N5O5S.1/4H2O

Molecular Weight

544.16

References & Citations

[1]Shah PP, et al. Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L. Mol Pharmacol. 2008 Jul;74 (1) :34-41.|[2]Pribis JP, et al. The HIV Protease Inhibitor Saquinavir Inhibits HMGB1-Driven Inflammation by Targeting the Interaction of Cathepsin V with TLR4/MyD88. Mol Med. 2015 Dec;21 (1) :749-757.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

Cathepsin L; Leishmania; Plasmodium

Citation 01

Signal Transduct Target Ther. 2023 Oct 11;8 (1) :390.|iScience. 2024 Oct 4;27 (11) :111024.|Nat Commun. 2020 Mar 27;11 (1) :1620.|Nat Commun. 2022 May 26;13 (1) :2935.|Signal Transduct Target Ther. 2021 Mar 27;6 (1) :134.